NASDAQ:ALLOAllogene Therapeutics Stock Price, Forecast & News

Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALLO stock has increased by 85.1% and is now trading at $46.36. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics.

Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allogene Therapeutics.

Allogene Therapeutics Inc (NASDAQ:ALLO) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.58) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.58). View Allogene Therapeutics' earnings history.

16 brokerages have issued twelve-month price objectives for Allogene Therapeutics' stock. Their forecasts range from $27.00 to $70.00. On average, they expect Allogene Therapeutics' stock price to reach $46.15 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View analysts' price targets for Allogene Therapeutics.

Media headlines about ALLO stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allogene Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAllogene Therapeutics.

Allogene Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 13,170,000 shares, a drop of 6.7% from the April 30th total of 14,110,000 shares. Based on an average daily trading volume, of 758,900 shares, the short-interest ratio is presently 17.4 days. Approximately 26.0% of the company's shares are short sold. View Allogene Therapeutics' Current Options Chain.

Some companies that are related to Allogene Therapeutics include Moderna (MRNA), NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP) and Ablynx (ABLYF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Teladoc Health (TDOC), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), bluebird bio (BLUE) and Sorrento Therapeutics (SRNE).

(ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO."

Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (7.16%), BlackRock Inc. (3.91%), Capital International Investors (3.65%), VV Manager LLC (1.83%), Alliancebernstein L.P. (1.58%) and State Street Corp (1.35%). Company insiders that own Allogene Therapeutics stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt and Group Holdings (Sbs) Advis Tpg. View institutional ownership trends for Allogene Therapeutics.

ALLO stock was sold by a variety of institutional investors in the last quarter, including VV Manager LLC, BlackRock Inc., Russell Investments Group Ltd., Morgan Stanley, Coastal Bridge Advisors LLC, Shikiar Asset Management Inc., Deutsche Bank AG, and Victory Capital Management Inc.. Company insiders that have sold Allogene Therapeutics company stock in the last year include Alison Moore, David D Chang, and Eric Thomas Schmidt. View insider buying and selling activity for Allogene Therapeutics.

ALLO stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Capital International Investors, Casdin Capital LLC, Rock Springs Capital Management LP, Eaton Vance Management, Alliancebernstein L.P., Tekla Capital Management LLC, and Wildcat Capital Management LLC. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang, and Group Holdings (Sbs) Advis Tpg. View insider buying and selling activity for Allogene Therapeutics.

Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLO stock can currently be purchased for approximately $46.36.

Allogene Therapeutics has a market capitalization of $5.81 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe.

The official website for Allogene Therapeutics is www.allogene.com.

Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected]